CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Bookmark and Share
Published: 17 Jun 2020
Views: 2948
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.

Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.

This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.